NYSEAMERICAN : TOVX
Theriva Biologics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.1825 USD (Oct 30, 2026, 10:05 AM EDT) · Market cap 8.38M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 7.06M | 6.42M | 6.70M | 7.78M | 7.57M | 6.47M |
| Research & Development | 5.31M | 8.60M | 12.03M | 14.31M | 11.72M | 7.80M |
| Operating Expenses | 12.37M | 15.02M | 18.73M | 22.09M | 19.29M | 14.27M |
| Operating Income | -12.07M | -15.02M | -18.73M | -22.09M | -19.29M | -14.27M |
| Interest & Investment Income | 298.00K | 287.00K | 697.00K | 1.44M | 512.00K | 6.00K |
| Currency Exchange Gain (Loss) | 8.00K | 25.00K | -4.00K | 3.00K | -41.00K | |
| EBT Excluding Unusual Items | -11.76M | -14.71M | -18.04M | -20.65M | -18.82M | -14.27M |
| Merger & Restructuring Charges | -200.00K | |||||
| Impairment of Goodwill | -5.59M | |||||
| Other Unusual Items | 142.00K | -9.03M | -699.00K | 660.00K | -2.09M | |
| Pretax Income | -11.62M | -23.74M | -25.65M | -19.99M | -21.11M | -14.27M |
| Income Tax Expense | -1.64M | -1.43M | ||||
| Earnings From Continuing Operations | -11.62M | -23.74M | -25.65M | -18.35M | -19.68M | -14.27M |
| Minority Interest in Earnings | 1.00K | |||||
| Net Income | -11.62M | -23.74M | -25.65M | -18.35M | -19.68M | -14.27M |
| Preferred Dividends & Other Adjustments | 1.51M | 1.51M | 340.00K | 8.92M | ||
| Net Income to Common | -13.13M | -25.25M | -25.65M | -18.35M | -20.02M | -23.19M |
| Shares Outstanding (Basic) | 31.50M | 12.14M | 1.35M | 644.28K | 613.09K | 487.50K |
| Shares Outstanding (Diluted) | 31.50M | 12.14M | 1.35M | 644.28K | 613.09K | 487.50K |
| EPS (Basic) | -0.42 | -2.08 | -19.03 | -28.48 | -32.66 | -47.57 |
| EPS (Diluted) | -0.42 | -2.08 | -19.03 | -28.48 | -32.66 | -47.57 |
| Free Cash Flow | -12.76M | -16.70M | -16.94M | -19.20M | -19.20M | -12.90M |
| Free Cash Flow Per Share | -0.41 | -1.38 | -12.56 | -29.80 | -31.31 | -26.47 |
| EBITDA | -11.96M | -14.91M | -18.59M | -21.96M | -19.20M | -14.19M |
| D&A For EBITDA | 103.00K | 108.00K | 137.00K | 135.00K | 85.00K | 87.00K |
| EBIT | -12.07M | -15.02M | -18.73M | -22.09M | -19.29M | -14.27M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 11.34M | 13.06M | 11.61M | 23.18M | 41.79M | 67.33M |
| Cash & Short-Term Investments | 11.34M | 13.06M | 11.61M | 23.18M | 41.79M | 67.33M |
| Other Receivables | 1.81M | 3.83M | 3.32M | 1.94M | 231.00K | |
| Receivables | 1.81M | 3.83M | 3.32M | 1.94M | 231.00K | |
| Prepaid Expenses | 462.00K | 576.00K | 984.00K | 1.17M | 1.21M | 1.07M |
| Other Current Assets | 63.00K | 365.00K | 1.12M | 2.29M | 458.00K | |
| Total Current Assets | 13.67M | 17.47M | 16.28M | 27.40M | 45.52M | 68.86M |
| Property, Plant & Equipment | 2.00M | 1.02M | 1.54M | 2.18M | 1.54M | 1.48M |
| Goodwill | 5.70M | 5.53M | ||||
| Long-Term Deferred Charges | 19.06M | 19.62M | 17.36M | 19.75M | 19.15M | |
| Other Long-Term Assets | 124.00K | 128.00K | 171.00K | 180.00K | 122.00K | 23.00K |
| Total Assets | 34.86M | 38.24M | 35.35M | 55.22M | 71.86M | 70.36M |
| Accounts Payable | 984.00K | 1.01M | 859.00K | 770.00K | 915.00K | 524.00K |
| Accrued Expenses | 6.71M | 6.72M | 4.51M | 4.51M | 2.90M | 2.91M |
| Current Portion of Long-Term Debt | 34.00K | 57.00K | 61.00K | 63.00K | 57.00K | |
| Current Portion of Leases | 525.00K | 549.00K | 539.00K | 487.00K | 216.00K | 124.00K |
| Other Current Liabilities | 3.86M | 1.68M | 1.61M | 906.00K | 2.97M | |
| Total Current Liabilities | 12.11M | 10.01M | 7.58M | 6.74M | 7.06M | 3.55M |
| Long-Term Debt | 1.62M | 1.67M | 92.00K | 162.00K | 221.00K | |
| Long-Term Leases | 1.37M | 352.00K | 873.00K | 1.44M | 1.19M | 1.40M |
| Long-Term Deferred Tax Liabilities | 1.62M | |||||
| Other Long-Term Liabilities | 7.57M | 10.82M | 7.74M | 7.18M | 7.21M | |
| Total Liabilities | 22.67M | 22.86M | 16.29M | 15.52M | 17.30M | 4.96M |
| Common Stock | 45.00K | 34.00K | 3.00K | 1.00K | 16.00K | 13.00K |
| Additional Paid-In Capital | 376.15M | 373.59M | 355.50M | 346.54M | 343.75M | 336.68M |
| Retained Earnings | -363.97M | -358.71M | -334.97M | -309.32M | -290.97M | -271.28M |
| Treasury Stock | -288.00K | -288.00K | -288.00K | -288.00K | -288.00K | |
| Comprehensive Income & Other | 247.00K | 755.00K | -1.18M | 32.00K | -679.00K | |
| Total Common Equity | 12.19M | 15.38M | 19.07M | 36.96M | 51.83M | 65.41M |
| Shareholders' Equity | 12.19M | 15.38M | 19.07M | 39.70M | 54.56M | 65.41M |
| Total Liabilities & Equity | 34.86M | 38.24M | 35.35M | 55.22M | 71.86M | 70.36M |
| Total Debt | 3.55M | 2.63M | 1.56M | 2.15M | 1.68M | 1.53M |
| Net Cash (Debt) | 7.78M | 10.43M | 10.04M | 21.02M | 40.10M | 65.80M |
| Net Cash Per Share | 0.25 | 0.86 | 7.45 | 32.63 | 65.41 | 134.97 |
| Filing Date Shares Outstanding | 45.89M | 45.89M | 2.78M | 685.92K | 604.96K | 633.75K |
| Total Common Shares Outstanding | 45.89M | 35.69M | 2.78M | 685.92K | 604.96K | 528.17K |
| Working Capital | 1.56M | 7.45M | 8.70M | 20.66M | 38.46M | 65.30M |
| Book Value Per Share | 0.27 | 0.43 | 6.85 | 53.89 | 85.67 | 123.84 |
| Tangible Book Value | 12.19M | 15.38M | 19.07M | 31.26M | 46.30M | 65.41M |
| Tangible Book Value Per Share | 0.27 | 0.43 | 6.85 | 45.58 | 76.54 | 123.84 |
| Machinery | 639.00K | 639.00K | 708.00K | 902.00K | 897.00K | 827.00K |
| Leasehold Improvements | 94.00K | 94.00K | 94.00K | 94.00K | 94.00K | 94.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -11.62M | -23.74M | -25.65M | -18.35M | -19.68M | -14.27M |
| Depreciation & Amortization | 103.00K | 108.00K | 137.00K | 135.00K | 85.00K | 87.00K |
| Loss (Gain) From Sale of Assets | 1.00K | 1.00K | ||||
| Asset Writedown & Restructuring Costs | 6.92M | |||||
| Stock-Based Compensation | 651.00K | 654.00K | 671.00K | 552.00K | 475.00K | 416.00K |
| Other Operating Activities | 31.00K | 9.37M | 263.00K | -3.64M | 849.00K | 165.00K |
| Change in Accounts Payable | 362.00K | 69.00K | 123.00K | -157.00K | -385.00K | -363.00K |
| Change in Other Net Operating Assets | -2.27M | -3.13M | 603.00K | 2.47M | -421.00K | 1.07M |
| Operating Cash Flow | -12.74M | -16.67M | -16.94M | -19.00M | -19.08M | -12.89M |
| Capital Expenditures | -22.00K | -35.00K | -1.00K | -202.00K | -116.00K | -14.00K |
| Cash Acquisitions | -3.86M | |||||
| Investing Cash Flow | -22.00K | -35.00K | -1.00K | -202.00K | -4.40M | -14.00K |
| Long-Term Debt Issued | 1.51M | |||||
| Long-Term Debt Repaid | -70.00K | -67.00K | -75.00K | -1.38M | ||
| Net Debt Issued (Repaid) | -14.00K | 1.44M | -67.00K | -75.00K | -1.38M | |
| Issuance of Common Stock | 13.08M | 17.47M | 5.56M | 2.22M | 74.00M | |
| Repurchase of Common Stock | -288.00K | |||||
| Other Financing Activities | -902.00K | -713.00K | -1.52M | -3.00M | ||
| Financing Cash Flow | 12.16M | 18.19M | 5.50M | 625.00K | -1.93M | 74.00M |
| Foreign Exchange Rate Adjustments | -183.00K | -92.00K | -132.00K | -33.00K | -32.00K | |
| Net Cash Flow | -785.00K | 1.40M | -11.57M | -18.61M | -25.44M | 61.10M |
| Free Cash Flow | -12.76M | -16.70M | -16.94M | -19.20M | -19.20M | -12.90M |
| Free Cash Flow Per Share | -0.41 | -1.38 | -12.56 | -29.80 | -31.31 | -26.47 |
| Levered Free Cash Flow | -6.69M | -5.98M | -10.55M | -14.41M | -10.42M | -7.51M |
| Unlevered Free Cash Flow | -6.69M | -5.98M | -10.55M | -14.41M | -10.42M | -7.51M |
| Change in Working Capital | -1.91M | -3.06M | 726.00K | 2.31M | -806.00K | 709.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 7.42M | 7.10M | 4.87M | 7.33M | 6.88M | 35.94M |
| Enterprise Value | -367.75K | 2.33M | -9.80M | -18.87M | -39.22M | -37.39M |
| Last Close Price | 0.17 | 0.21 | 1.75 | 10.75 | 11.37 | 68.05 |
| PB Ratio | 0.64 | 0.46 | 0.26 | 0.18 | 0.13 | 0.55 |
| P/TBV Ratio | 0.64 | 0.46 | 0.26 | 0.23 | 0.15 | 0.55 |
| Debt / Equity Ratio | 0.29 | 0.17 | 0.08 | 0.05 | 0.03 | 0.02 |
| Net Debt / Equity Ratio | -0.64 | -0.68 | -0.53 | -0.53 | -0.73 | -1.01 |
| Net Debt / EBITDA Ratio | 0.65 | 0.70 | 0.54 | 0.96 | 2.09 | 4.64 |
| Net Debt / FCF Ratio | 0.61 | 0.62 | 0.59 | 1.09 | 2.09 | 5.10 |
| Quick Ratio | 1.08 | 1.69 | 1.97 | 3.73 | 5.95 | 18.94 |
| Current Ratio | 1.13 | 1.74 | 2.15 | 4.07 | 6.45 | 19.38 |
| Return on Equity (ROE) | -101.87% | -137.82% | -87.31% | -38.93% | -32.82% | -40.38% |
| Return on Assets (ROA) | -21.34% | -25.51% | -25.85% | -21.73% | -16.95% | -22.65% |
| Return on Capital Employed (ROCE) | -53.00% | -53.20% | -67.40% | -45.60% | -29.80% | -21.40% |
| Earnings Yield | -257.90% | -334.41% | -526.83% | -250.32% | -286.19% | -39.70% |
| FCF Yield | -163.12% | -235.31% | -347.85% | -261.91% | -279.10% | -35.90% |
| Buyback Yield / Dilution | -834.13% | -800.56% | -109.24% | -5.09% | -25.76% | -541.07% |